Last reviewed · How we verify
Nu-Lytely
Nu-Lytely is a Small molecule drug developed by Ascension Health. It is currently FDA-approved. Also known as: Polyethylene Glycol 3350, PEG 3350.
Nu-Lytely is a small molecule used to treat Clostridium Difficile Colitis. It is administered through oral lavage as part of the treatment protocol.
At a glance
| Generic name | Nu-Lytely |
|---|---|
| Also known as | Polyethylene Glycol 3350, PEG 3350 |
| Sponsor | Ascension Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nu-Lytely CI brief — competitive landscape report
- Nu-Lytely updates RSS · CI watch RSS
- Ascension Health portfolio CI
Frequently asked questions about Nu-Lytely
What is Nu-Lytely?
Nu-Lytely is a Small molecule drug developed by Ascension Health.
Who makes Nu-Lytely?
Nu-Lytely is developed and marketed by Ascension Health (see full Ascension Health pipeline at /company/ascension-health).
Is Nu-Lytely also known as anything else?
Nu-Lytely is also known as Polyethylene Glycol 3350, PEG 3350.
What development phase is Nu-Lytely in?
Nu-Lytely is FDA-approved (marketed).
Related
- Manufacturer: Ascension Health — full pipeline
- Also known as: Polyethylene Glycol 3350, PEG 3350
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing